SCHEMBL3582255

SCHEMBL3582255

C[C@H](c1ccccc1)N1CC[C@H]2CN(C(=O)O)C[C@H]21

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CCR5 P51681 1/20 0.42
HTR1A P08908 2/20 0.40
CHRM3 P20309 5/20 0.40
CHRM2 P08172 3/20 0.40
CHRM4 P08173 3/20 0.40
CHRM5 P08912 3/20 0.40
CHRM1 P11229 3/20 0.40
KMT2A Q03164 1/20 0.40
ALDH1A1 P00352 2/20 0.39
CHRNB4 P30926 1/20 0.39
CHRNA3 P32297 1/20 0.39
CYP2D6 P10635 2/20 0.39
OPRM1 P35372 1/20 0.39
OPRD1 P41143 1/20 0.39
OPRK1 P41145 1/20 0.39
OPRL1 P41146 1/20 0.39
HPGD P15428 1/20 0.39
MAPK1 P28482 1/20 0.38
HTT P42858 1/20 0.37
KDM4E B2RXH2 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3575935 1.00 CCR5 (0.42) CCR5HTR1ACHRM3CHRM2CHRM4
SCHEMBL5130929 1.00 CCR5 (0.42) CCR5HTR1ACHRM3CHRM2CHRM4
SCHEMBL7687290 1.00 CCR5 (0.42) CCR5HTR1ACHRM3CHRM2CHRM4
SCHEMBL19467730 1.00 CCR5 (0.42) CCR5HTR1ACHRM3CHRM2CHRM4
SCHEMBL12066936 0.88 ALDH1A1 (0.48) CCR5HTR1ACHRM3CHRM2CHRM4
SCHEMBL15096693 0.88 ALDH1A1 (0.48) CCR5HTR1ACHRM3CHRM2CHRM4
SCHEMBL8147886 0.87 CYP2D6 (0.43) CCR5HTR1ACHRM3CHRM2CHRM4
SCHEMBL649724 0.86 DPP4 (0.42) CCR5HTR1ACHRM3CHRM2CHRM4
SCHEMBL654325 0.86 DPP4 (0.42) CCR5HTR1ACHRM3CHRM2CHRM4
SCHEMBL653594 0.85 TSHR (0.49) CHRM2CHRM5CHRM1ALDH1A1CYP2D6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120208820-A1 DIAZABICYCLIC CENTRAL NERVOUS SYSTEM ACTIVE AGENTS SCHRIMPF MICHAEL R (US) 2012-08-16 US disclosed
US-20100016277-A1 DIAZABICYCLIC CENTRAL NERVOUS SYSTEM ACTIVE AGENTS ABBOTT LABORATORIES (US) 2010-01-21 US disclosed
US-7319106-B2 Diazabicyclic central nervous system active agents ABBOTT LABORATORIES (US) 2008-01-15 US disclosed
US-6809105-B2 (CIS)-6-(3-PYRIDINYL)-3,6-DIAZABICYCLO(3.2.0) HEPTANE FOR EXAMPLE; ALZHEIMER'S DISEASE, PARKINSON'S DISEASE, ATTENTION DEFICIT HYPERACTIVITY DISORDER, DEPRESSION, NICOTINIC WITHDRAWAL SYNDROME, TOURETTE'S SYNDROME, AND SCHIZOPHRENIA ABBOTT LABORATORIES 2004-10-26 US disclosed
US-20040186107-A1 Diazabicyclic central nervous system active agents ABBVIE INC. 2004-09-23 US disclosed
US-20020019388-A1 Diazabicyclic central nervous system active agents ABBVIE INC. 2002-02-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120208820-A1 DIAZABICYCLIC CENTRAL NERVOUS SYSTEM ACTIVE AGENTS GAP43, GABRE, CHRNA6 CCR5 2251/4885HTR1A 998/4885CHRM3 101/4885
US-20020019388-A1 Diazabicyclic central nervous system active agents GAP43, GABRE, CHRNA6 CCR5 2192/4885HTR1A 724/4885CHRM3 102/4885
US-20100016277-A1 DIAZABICYCLIC CENTRAL NERVOUS SYSTEM ACTIVE AGENTS GAP43, GABRE, CHRNA6 CCR5 2251/4885HTR1A 998/4885CHRM3 101/4885
US-20040186107-A1 Diazabicyclic central nervous system active agents GAP43, GABRE, CHRNA6 CCR5 2192/4885HTR1A 724/4885CHRM3 102/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.